Search

Your search keyword '"Dell'Acqua, V"' showing total 174 results
Start Over Author "Dell'Acqua, V"
174 results on '"Dell'Acqua, V"'

1. Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

Author

Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, and Franco P

Subjects
NLR, PLR, SII, Anal cancer, prognostic factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Andrea Casadei-Gardini,1 Francesco Montagnani,2 Chiara Casadei,1 Francesca Arcadipane,3 Kalliopi Andrikou,4 Deborah Aloi,5 Alessandra Anna Prete,6,7 Maria Giulia Zampino,8 Antonella Argentiero,9 Giuseppe Pugliese,4 Stefania Martini,10 Giuseppe Carlo Iorio,10 Mario Scartozzi,11 Massimiliano Mistrangelo,12 Lorenzo Fornaro,13 Paola Cassoni,14 Giorgia Marisi,15 Veronica Dell’Acqua,16 Paola Simona Ravenda,8 Sara Lonardi,6 Nicola Silvestris,7 Berardino De Bari,5 Umberto Ricardi,3 Stefano Cascinu,4 Pierfrancesco Franco91Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; 2Oncology Department, SOC Oncology, ASL (Health Local Authority), Biella, Italy; 3Department of Oncology, Radiation Oncology, AOU Città della Salute e della Scienza, Turin, Italy; 4Department of Hematology and Oncology, University of Modena and Reggio Emilia, Modena, Italy; 5Radiation Oncology Department, Centre Hospitalier Régional Universitaire “Jean Minjoz”, Besançon Cedex, France; 6Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy; 7Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I University Hospital, Rome, Italy; 8Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy; 9Medical Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy; 10Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy; 11Department of Medical Oncology, University of Cagliari, Cagliari, Italy; 12Department of Surgical Sciences, University of Turin, Turin, Italy; 13Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana University, Pisa, Italy; 14Department of Medical Sciences, Pathology Unit, University of Turin, Turin, Italy; 15Biosciences Laboratory, Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy; 16Department of Radiotherapy, IRCCS, European Institute of Oncology, Milan, ItalyBackground: In anal cancer, there are no markers nor other laboratory indexes that can predict prognosis and guide clinical practice for patients treated with concurrent chemoradiation. In this study, we retrospectively investigated the influence of immune inflammation indicators on treatment outcome of anal cancer patients undergoing concurrent chemoradiotherapy.Methods: All patients had a histologically proven diagnosis of squamous cell carcinoma of the anal canal/margin treated with chemoradiotherapy according to the Nigro’s regimen. Impact on prognosis of pre-treatment systemic index of inflammation (SII) (platelet x neutrophil/lymphocyte), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were analyzed.Results: A total of 161 consecutive patients were available for the analysis. Response to treatment was the single most important factor for progression-free survival (PFS) and overall survival (OS). At univariate analysis, higher SII level was significantly correlated to lower PFS (p

Published
2019

4. Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT

Author

Dell’Acqua, V., Kobiela, J., Kraja, F., Leonardi, M. C., Surgo, A., Zerella, M. A., Arculeo, S., Fodor, C., Ricotti, R., Zampino, M. G., Ravenda, S., Spinoglio, G., Biffi, R., Bazani, A., Luraschi, R., Vigorito, S., Spychalski, P., Orecchia, R., Glynne-Jones, R., and Jereczek-Fossa, B. A.

Published
2018
Full Text
View/download PDF

5. Brain metastases from primary colorectal cancer: Is radiosurgery an effective treatment approach? Results of a multicenter study of the radiation and clinical oncology Italian association (AIRO)

Author

Navarria, P, Minniti, G, Clerici, E, Comito, T, Cozzi, S, Pinzi, V, Fariselli, L, Ciammella, P, Scoccianti, S, Borzillo, V, Anselmo, P, Maranzano, E, Dell'Acqua, V, Jereczek-Fossa, B, Levra, N, Podlesko, A, Giudice, E, Di Monale E Bastia, M, Pedretti, S, Bruni, A, Zanetti, I, Borghesi, S, Busato, F, Pasqualetti, F, Paiar, F, Scorsetti, M, Navarria P., Minniti G., Clerici E., Comito T., Cozzi S., Pinzi V., Fariselli L., Ciammella P., Scoccianti S., Borzillo V., Anselmo P., Maranzano E., Dell'Acqua V., Jereczek-Fossa B., Levra N. G., Podlesko A. M., Giudice E., Di Monale E Bastia M. B., Pedretti S., Bruni A., Zanetti I. B., Borghesi S., Busato F., Pasqualetti F., Paiar F., Scorsetti M., Navarria, P, Minniti, G, Clerici, E, Comito, T, Cozzi, S, Pinzi, V, Fariselli, L, Ciammella, P, Scoccianti, S, Borzillo, V, Anselmo, P, Maranzano, E, Dell'Acqua, V, Jereczek-Fossa, B, Levra, N, Podlesko, A, Giudice, E, Di Monale E Bastia, M, Pedretti, S, Bruni, A, Zanetti, I, Borghesi, S, Busato, F, Pasqualetti, F, Paiar, F, Scorsetti, M, Navarria P., Minniti G., Clerici E., Comito T., Cozzi S., Pinzi V., Fariselli L., Ciammella P., Scoccianti S., Borzillo V., Anselmo P., Maranzano E., Dell'Acqua V., Jereczek-Fossa B., Levra N. G., Podlesko A. M., Giudice E., Di Monale E Bastia M. B., Pedretti S., Bruni A., Zanetti I. B., Borghesi S., Busato F., Pasqualetti F., Paiar F., and Scorsetti M.

Abstract

Objectives: The prognosis of brain metastatic colorectal cancer patients (BMCRC) is poor. Several local treatments have been used, but the optimal treatment choice remains an unresolved issue. We evaluated the clinical outcomes of a large series of BMCRC patients treated in several Italian centers using stereotactic radiosurgery (SRS). Methods: 185 BMCRC patients for a total of 262 lesions treated were evaluated. Treatments included surgery followed by post-operative SRS to the resection cavity, and SRS, either single-fraction, then hypofractionated SRS (HSRS). Outcomes was measured in terms of local control (LC), toxicities, brain distant failure (BDF), and overall survival (OS). Prognostic factors influencing survival were assed too. Results: The median follow-up time was 33 months (range 3-183 months). Surgery plus SRS have been performed in 28 (10.7%) cases, SRS in 141 (53.8%), and HSRS in 93 (35.5%). 77 (41.6%) patients received systemic therapy. The main total dose and fractionation used were 24Gy in single fraction or 24Gy in three daily fractions. Local recurrence occurred in 32 (17.3%) patients. Median, 6 months,1-year-LC were 86 months (95%CI 36-86), 87.2% ± 2.8, 77.8% ± 4.1. Median,6 months,1-year-BDF were 23 months (95%CI 9-44), 66.4% ± 3.9, 55.3% ± 4.5. Median,6 months,1-year-OS were 7 months (95%CI 6-9), 52.7% ± 3.6, 33% ± 3.5. No severe neurological toxicity occurred. Stage at diagnosis, Karnofsky Performance Status (KPS), presence and number of extracranial metastases, and disease-specific-graded-prognostic-assessment (DS-GPA) score were observed as conditioning survival. Conclusion: SRS/HSRS have proven to be an effective local treatment for BMCRC. A careful evaluation of prognostic factors as well as a multidisciplinary evaluation is a valid aid to manage the optimal therapeutic strategy for CTC patients with BMs.

Published
2020

6. Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center

Author

Rotundo, M, Zampino, M, Ravenda, P, Bagnardi, V, Peveri, G, Dell'Acqua, V, Surgo, A, Trovato, C, Bottiglieri, L, Bertani, E, Petz, W, Fumagalli Romario, U, Fazio, N, Rotundo M. S., Zampino M. G., Ravenda P. S., Bagnardi V., Peveri G., Dell'Acqua V., Surgo A., Trovato C., Bottiglieri L., Bertani E., Petz W. L., Fumagalli Romario U., Fazio N., Rotundo, M, Zampino, M, Ravenda, P, Bagnardi, V, Peveri, G, Dell'Acqua, V, Surgo, A, Trovato, C, Bottiglieri, L, Bertani, E, Petz, W, Fumagalli Romario, U, Fazio, N, Rotundo M. S., Zampino M. G., Ravenda P. S., Bagnardi V., Peveri G., Dell'Acqua V., Surgo A., Trovato C., Bottiglieri L., Bertani E., Petz W. L., Fumagalli Romario U., and Fazio N.

Abstract

Background and Aims: The standard treatment of non-metastatic anal squamous cell carcinoma (ASCC) consists of chemotherapy with mitomycin (MMC) plus 5-fluorouracil (5FU) for 1–2 cycles concomitant with pelvic radiotherapy. Subsequent studies introduced cisplatin (CDDP) combined with 5FU, with unclear results. We evaluated the doublet capecitabine (C) and CDDP as a possible alternative to MMC-5FU regimen concomitant with intensity-modulated radiation therapy (IMRT). Patients and Methods: We carried out a retrospective study on 67 patients affected by stage I–III ASCC, treated with CDDP (60–70 mg/m2 every 21 days for two courses) plus C (825 mg/m2 twice daily for 5 days/week) chemotherapy concomitant with IMRT for curative intent. Results: At a median follow up of 41 months, the clinical complete response calculated at the 6-month time-point (6-moCR), the 6-month objective response rate and the 6-month disease control rate were 93%, 94%, and 99%, respectively. Disease-free survival rates at 1, 2, and 3 years were 89%, 87%, and 85%, while the overall survival rates at 1 and 2 years were 100% and 95%. The colostomy-free survival rates were 90% at 1 year and 88% at 2 years. Grade 3–4 acute adverse events were reported in 61% of patients; predominantly skin toxicity (46%) and limited hematological toxicity (12%). Conclusion: In this retrospective study, chemotherapy with C plus CDDP concomitant with IMRT proved safe and effective, and may represent a possible alternative option to standard MMC-containing regimen for curative intent.

Published
2020

7. Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series

Author

Leonardi, M, Corrao, G, Frassoni, S, Vingiani, A, Dicuonzo, S, Lazzeroni, M, Fodor, C, Morra, A, Gerardi, M, Rojas, D, Dell'Acqua, V, Marvaso, G, Bassi, F, Galimberti, V, Veronesi, P, Miglietta, E, Cattani, F, Zurrida, S, Bagnardi, V, Viale, G, Orecchia, R, Jereczek-Fossa, B, Leonardi M. C., Corrao Giulia, Frassoni S., Vingiani A., Dicuonzo S., Lazzeroni M., Fodor C., Morra Anna, Gerardi M. A., Rojas D. P., Dell'Acqua V., Marvaso G., Bassi F. D., Galimberti V. E., Veronesi P., Miglietta E., Cattani F., Zurrida S., Bagnardi V., Viale G., Orecchia R., Jereczek-Fossa B. A., Leonardi, M, Corrao, G, Frassoni, S, Vingiani, A, Dicuonzo, S, Lazzeroni, M, Fodor, C, Morra, A, Gerardi, M, Rojas, D, Dell'Acqua, V, Marvaso, G, Bassi, F, Galimberti, V, Veronesi, P, Miglietta, E, Cattani, F, Zurrida, S, Bagnardi, V, Viale, G, Orecchia, R, Jereczek-Fossa, B, Leonardi M. C., Corrao Giulia, Frassoni S., Vingiani A., Dicuonzo S., Lazzeroni M., Fodor C., Morra Anna, Gerardi M. A., Rojas D. P., Dell'Acqua V., Marvaso G., Bassi F. D., Galimberti V. E., Veronesi P., Miglietta E., Cattani F., Zurrida S., Bagnardi V., Viale G., Orecchia R., and Jereczek-Fossa B. A.

Abstract

Aims: To report the long-term outcome of a single institution series of pure ductal carcinoma in situ (DCIS) treated with accelerated partial irradiation using intraoperative electrons (IOERT). Methods: From 2000 to 2010, 180 DCIS patients, treated with quadrantectomy and 21 Gy IOERT, were analyzed in terms of ipsilateral breast recurrences (IBRs) and survival outcomes by stratification in two subgroups. The low-risk group included patients who fulfilled the suitable definition according to American Society of Radiation Oncology (ASTRO) Guidelines (size ≤2.5 cm, grade 1–2 and surgical margins ≥3 mm) (Suitable), while the remaining ones formed the high-risk group (Non-Suitable). Results: Eighty-four and 96 patients formed the Suitable and Non-Suitable groups, respectively. In the whole population, the cumulative incidence of IBR at 5, 7 and 10 years was 19%, 21%, and 25%, respectively. In the Suitable group, the cumulative incidence of IBR remained constant at 11% throughout the years, while in the Non-Suitable group increased from 26% at 5 years to 36% at 10 years (p < 0.0001). When hormonal positivity and HER2 absence of expression were added to the selection of the Suitable group, the cumulative incidence of IBR dropped and stabilized at 4% at 10 years. None died of breast cancer. In the whole population, 5-year and 10-year overall survival rate was 98% and 96.5%, respectively, without any difference between the two groups. Conclusions: The overall and by group IBR rates were high and stricter criteria are required for acceptable local control for Suitable DCIS. Because of the concerns raised, IOERT should not be used in clinical practice.

Published
2019

8. Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy

Author

Dell'Acqua, V, Surgo, A, Arculeo, S, Zerella, M, Bagnardi, V, Frassoni, S, Zampino, M, Ravenda, P, Rotundo, M, Kraja, F, Kobiela, J, Spychalski, P, Fodor, C, Gerardi, M, Cattani, F, Bazani, A, Petz, W, Glynne-Jones, R, Orecchia, R, Leonardi, M, Jereczek-Fossa, B, Dell'Acqua, Veronica, Surgo, Alessia, Arculeo, Simona, Zerella, Maria Alessia, Bagnardi, Vincenzo, Frassoni, Samuele, Zampino, Maria Giulia, Ravenda, Paola Simona, Rotundo, Maria Saveria, Kraja, Fatjona, Kobiela, Jarek, Spychalski, Piotr, Fodor, Cristiana, Gerardi, Marianna Alessandra, Cattani, Federica, Bazani, Alessia, Petz, Wanda, Glynne-Jones, Robert, Orecchia, Roberto, Leonardi, Maria Cristina, Jereczek-Fossa, Barbara Alicja, Dell'Acqua, V, Surgo, A, Arculeo, S, Zerella, M, Bagnardi, V, Frassoni, S, Zampino, M, Ravenda, P, Rotundo, M, Kraja, F, Kobiela, J, Spychalski, P, Fodor, C, Gerardi, M, Cattani, F, Bazani, A, Petz, W, Glynne-Jones, R, Orecchia, R, Leonardi, M, Jereczek-Fossa, B, Dell'Acqua, Veronica, Surgo, Alessia, Arculeo, Simona, Zerella, Maria Alessia, Bagnardi, Vincenzo, Frassoni, Samuele, Zampino, Maria Giulia, Ravenda, Paola Simona, Rotundo, Maria Saveria, Kraja, Fatjona, Kobiela, Jarek, Spychalski, Piotr, Fodor, Cristiana, Gerardi, Marianna Alessandra, Cattani, Federica, Bazani, Alessia, Petz, Wanda, Glynne-Jones, Robert, Orecchia, Roberto, Leonardi, Maria Cristina, and Jereczek-Fossa, Barbara Alicja

Abstract

Purpose: To retrospectively review our experience on 84 patients with squamous cell anal canal cancer (SCAC) within 12 months after combined treatment with intensity-modulated RT (IMRT), in terms of acute and early-late toxicity, overall treatment time and interruptions, colostomy-free survival (CFS), and tumor response. Methods: Acute gastrointestinal (GI), genitourinary (GU), and cutaneous (CU) toxicities were assessed according to Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03. Early-late toxicity was scored using the Radiation Therapy Oncology Group (RTOG) late radiation morbidity scoring system. Tumor response was evaluated with response evaluation criteria in solid tumors (RECIST) v1.1. Results: Acute toxicity for 84 subjects (100%): severe (≥ G3) GI and skin toxicity was observed in 4 (5%) and 19 patients (23%), respectively. Early-late toxicity for 73 subjects (87%): severe (≥ G3) GI and vulvo-vaginal toxicity was observed in 2 (3%) and 2 (3%) patients, respectively. No acute or early-late severe GU toxicity was reported. A treatment interruption occurred in 65 patients (77%). CFS was 96% (95% CI 89–99) at 6 months and 92% (95% CI 83–96) at 12 months. At 6 months complete response (CR), partial response (PR) and progressive disease (PD) was observed in 70 (83%), 3 (4%), and 7 patients (8%), respectively. At 12 months, CR was observed in 60 patients (81%); eleven patients (15%) experienced PD. Conclusion: Our study showed an excellent clinical result and very low acute toxicity rates, confirming the IMRT as standard of care for curative treatment of anal cancer patients. The current trial was registered with the number IEO N87/11

Published
2020

9. Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy

Author

Lüftner D, Dell’Acqua V, Selle F, Khalil A, Leonardi MC, De La Torre Tomás A, Shenouda G, Romero Fernandez J, Orecchia R, Moyal D, and Seité S

Subjects
palliative care, dermatological toxicity, dermocosmetic, chemotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Skin care, lcsh:RC254-282
Abstract

Diana Lüftner,1 Veronica Dell’Acqua,2 Frédéric Selle,3 Ahmed Khalil,3 Maria Cristina Leonardi,2 Alejandro De La Torre Tomás,4 George Shenouda,5 Jesus Romero Fernandez,4 Roberto Orecchia,2,6 Dominique Moyal,7 Sophie Seité7 1Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; 2Department of Radiotherapy, IEO, European Institute of Oncology IRCCS, Milan, Italy; 3Tenon Hospital, Paris, France; 4Puerta de Hierro Hospital, Madrid, Spain; 5McGill Hospital, Montreal, Canada; 6Milan University, Milan, Italy; 7La Roche-Posay Dermatological Laboratory, Levallois-Perret, France Introduction: The purpose of this multicenter, prospective, observational, open-label study was to evaluate the use and tolerability of dermo-cosmetic products in preventing skin reactions associated with cancer treatments. Patients and methods: A 12-product kit was supplied to patients before chemotherapy began and was to be used throughout the treatment phase. Cutaneous adverse events were evaluated at each treatment session. Physicians evaluated skin reactions (edema, erythema, dryness, desquamation, pigmentation disorders, and cracks) and gave their opinion on the skin benefit for patients at the end of the study. Patients also evaluated the product benefit using the Patient Benefit Index (PBI) questionnaire. Results were analyzed by subgroups of casual and regular users, based on number and frequency of products used. Results: A total of 147 patients were enrolled in cancer services in Germany, France, Italy, Spain, and Canada. Mean age was 59 years with 71% being female. Product tolerance on whole body was rated good to excellent for at least 89% of the patients for each product. Aggravated skin reactions during the study were reported more frequently by casual users than regular users (39.5% versus 22%; p=0.029). Similarly, casual users reported more erythema aggravation (p=0.02) and desquamation (p=0.03) than regular users. PBI >1 was reported for 95.5% of patients and regular users had significantly higher scores than casual users (p=0.049). Discussion: Overall, the 12-product kit was very well tolerated, with regular users reporting benefits more frequently than casual users. Results support international recommendations to use appropriate skin care products to minimize the impact of cutaneous reactions associated with chemotherapy. Keywords: dermocosmetic, dermatological toxicity, skin side effect, skin reaction, palliative care

Published
2018

10. PO-0937: Partial breast re-irradiation with IMRT for local recurrence after whole breast radiotherapy

Author

Arculeo, S., primary, Frassoni, S., additional, Cavallo, I., additional, Dicuonzo, S., additional, Gerardi, M.A., additional, Morra, A., additional, Dell'Acqua, V., additional, Cattani, F., additional, Comi, S., additional, Veronesi, P., additional, Pansini, F., additional, Galimberti, V., additional, Fodor, C., additional, Bagnardi, V., additional, Orecchia, R., additional, Leonardi, M.C., additional, and Jereczek-Fossa, B.A., additional

Published
2020
Full Text
View/download PDF

11. PO-0880: SRS in brain metastases from colorectalcancer. A Radiation Oncology Italian Association study

Author

Navarria, P., primary, Clerici, E., additional, Comito, T., additional, Cozzi, S., additional, Pinzi, V., additional, Ciammella, P., additional, Scoccianti, S., additional, Borzillo, V., additional, Anselmo, P., additional, Maranzano, E., additional, Dell'acqua, V., additional, Jereczek-Fossa, B., additional, Levra, N. Giaj, additional, Minniti, G., additional, Podlesko, A.M., additional, Giudice, E., additional, di Monale e Bastia, M. Buglione, additional, Pedretti, S., additional, Bruni, A., additional, Zanetti, I. Bssi, additional, Borgesi, S., additional, Busato, F., additional, and Scorsetti, M., additional

Published
2020
Full Text
View/download PDF

12. PD-0295: FAST approach in early breast cancer irradiation: toxicity and outcome in a 3DCRT vs IMRT comparison

Author

Zerella, M.A., primary, Arculeo, S., additional, Dicuonzo, S., additional, Dell'Acqua, V., additional, Gerardi, M.A., additional, Morra, A., additional, Bergamaschi, L., additional, Frassoni, S., additional, Bagnardi, V., additional, Fodor, C., additional, Cattani, F., additional, Galimberti, V., additional, Veronesi, P., additional, Orecchia, R., additional, Leonardi, M.C., additional, and Jereczek-Fossa, B.A., additional

Published
2020
Full Text
View/download PDF

14. PO-0819 Stereotactic Radiation Therapy in Oligometastatic Colorectal Cancer: 102 patients and 150 lesions

Author

ZERELLA, M.A., primary, Dell'Acqua, V., additional, Surgo, A., additional, Pupuleku, F. Kraja, additional, Kobiela, J., additional, Spychalski, P., additional, Francia, C.M., additional, Ciardo, D., additional, Fodor, C., additional, Pansini, F., additional, Vigorito, S., additional, Cattani, F., additional, Leonardi, M.C., additional, and Fossa, B.A. Jereczek, additional

Published
2019
Full Text
View/download PDF

15. EP-1315 The FAST approach as adjuvant whole breast irradiation for frail breast cancer patients

Author

Zerella, M.A., primary, Arculeo, S., additional, Miglietta, E., additional, Casbarra, A., additional, Dicuonzo, S., additional, Dell'Acqua, V., additional, Gerardi, M.A., additional, Morra, A., additional, Fodor, C., additional, Cattani, F., additional, Galimberti, V.E., additional, Veronesi, P., additional, Orecchia, R., additional, Leonardi, M.C., additional, and Jereczek-Fossa, B.A., additional

Published
2019
Full Text
View/download PDF

16. EP-1310 Toxicity evaluation of a hypofractionated WBRT with SIB for breast cancer using TomoDirect

Author

Dicuonzo, S., primary, Leonardi, M.C., additional, Raimondi, S., additional, Miglietta, E., additional, Gerardi, M.A., additional, Morra, A., additional, Dell'Acqua, V., additional, Surgo, A., additional, Rojas, D.P., additional, Pansini, F., additional, Luraschi, R., additional, Cattani, F., additional, Fodor, C., additional, Veronesi, P., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2019
Full Text
View/download PDF

17. Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): Preliminary results

Author

Ravenda, P., primary, Gregato, G., additional, Rotundo, M., additional, Frassoni, S., additional, Dell'Acqua, V., additional, Trovato, C., additional, Petz, W., additional, Raviele, P. Rafaniello, additional, Bagnardi, V., additional, Bertolini, F., additional, and Zampino, M., additional

Published
2018
Full Text
View/download PDF

18. EP-1326: Hypofractionated IMRT using Tomotherapy for early stage breast cancer: early chronic toxicity

Author

Dicuonzo, S., primary, Raimondi, S., additional, Surgo, A., additional, Spoto, R., additional, Gerardi, M., additional, Morra, A., additional, Ricotti, R., additional, Dell'acqua, V., additional, Casbarra, A., additional, Arculeo, S., additional, Rojas, D., additional, Luraschi, R., additional, Cattani, F., additional, Fodor, C., additional, Veronesi, P., additional, Orecchia, R., additional, Leonardi, M., additional, and Jereczek, B., additional

Published
2018
Full Text
View/download PDF

19. EP-1323: Dosimetry results and toxicity of a 3-week schedule RT with SIB in breast cancer, with TomoDirect

Author

Gerardi, M., primary, Morra, A., additional, Dicuonzo, S., additional, Arculeo, S., additional, Patti, F., additional, Ricotti, R., additional, Dell'Acqua, V., additional, Augugliaro, M., additional, Arrobbio, C., additional, Viola, A., additional, Rojas, D., additional, Fodor, C., additional, Emiro, F., additional, Cattani, F., additional, Raimondi, S., additional, Galimberti, V., additional, Orecchia, R., additional, Leonardi, M., additional, and Jereczek-Fossa, B., additional

Published
2018
Full Text
View/download PDF

20. SP-0653: Hypofractionation for breast cancer: 30, 15 or 5 fractions?

Author

Leonardi, M.C., primary, Morra, A., additional, Dicuonzo, S., additional, Gerardi, M., additional, Dell'Acqua, V., additional, Rojas, D., additional, Surgo, A., additional, Arculeo, S., additional, Casbarra, A., additional, Arrobbio, C., additional, Spoto, R., additional, Cattani, F., additional, Orecchia, R., additional, and Jereczek Fossa, B., additional

Published
2018
Full Text
View/download PDF

21. EP-1344: Long-term reconstruction failure after postmastectomy RT to temporary expander or permanent implant

Author

Dicuonzo, S., primary, Leonardi, M., additional, Radice, D., additional, Morra, A., additional, Dell'Acqua, V., additional, Gerardi, M., additional, Rojas, D., additional, Surgo, A., additional, Cattani, F., additional, Cambria, R., additional, Fodor, C., additional, De Lorenzi, F., additional, Galimberti, V., additional, Orecchia, R., additional, and Jereczek-Fossa, B., additional

Published
2018
Full Text
View/download PDF

22. The role of [18F]FDG-PET/CT in staging and treatment planning for volumetric modulated Rapidarc radiotherapy in cervical cancer: Experience of the European Institute of Oncology, Milan, Italy

Author

Lazzari, R, Cecconi, A, Jereczek-Fossa, B, Travaini, L, Dell'Acqua, V, Cattani, F, Rizzo, S, Fodor, C, Landoni, F, Orecchia, R, Lazzari R., Cecconi A., Jereczek-Fossa B. A., Travaini L. L., Dell'Acqua V., Cattani F., Rizzo S., Fodor C., Landoni F., Orecchia R., Lazzari, R, Cecconi, A, Jereczek-Fossa, B, Travaini, L, Dell'Acqua, V, Cattani, F, Rizzo, S, Fodor, C, Landoni, F, Orecchia, R, Lazzari R., Cecconi A., Jereczek-Fossa B. A., Travaini L. L., Dell'Acqua V., Cattani F., Rizzo S., Fodor C., Landoni F., and Orecchia R.

Abstract

Rationale: to evaluate the role of 18F-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) integrated with computer tomography (CT) scan [18F]FDG-PET/CT in the staging and target volume definition in Intensity Modulated RapidarcTM Delivery (RA-IMRT) in cervical cancer. Methods: From June 2010 to December 2011, 66 patients affected by cervical cancer, candidates for definitive or adjuvant radiochemotherapy, underwent standard staging with CT and magnetic resonance imaging (MRI). All patients underwent [18F]FDG-PET/CT in order to exclude distant metastases and to define gross tumor volume (GTV). 40 and 26 patients received exclusive and adjuvant radiotherapy, respectively. RA-IMRT with simultaneous integrated boost (SIB) to the positive disease technique was employed. Results: [18F]FDG-PET/CT has changed the stage, and radiotherapy treatment planning was modified in 25% and 7.7% of patients that received definitive and adjuvant radiotherapy, respectively. Particularly [18F]FDG-PET/CT imaging showed metabolically active tumor in lymph nodes area, therefore the stage and the treatment planning changed for these patients. Conclusions: [ 18F]FDG-PET/CT leads to a better staging and definition of disease and has the potential of showing lymph-node metastasis not only within the pelvis but also in the para-aortic area. In addition, [18F]FDG-PET/CT is useful for better definition of the target volume and to produce a 'dose painted' treatment. This might also open the field for escalation dose regimens. © the authors; licensee ecancermedicalscience.

Published
2014

23. Intraoperative Retrograde Perfusion Sphincterometry to Evaluate Efficacy of Autologous Vas Deferens 6-Branch Suburethral Sling to Properly Restore Sphincteric Apparatus During Robot-Assisted Radical Prostatectomy

Author

Cestari, A, Soranna, D, Zanni, G, Zambon, A, Zanoni, M, Sangalli, M, Ghezzi, M, Fabbri, F, Sozzi, F, Dell'Acqua, V, Rigatti, P, SORANNA, DAVIDE, ZAMBON, ANTONELLA, Rigatti, P., Cestari, A, Soranna, D, Zanni, G, Zambon, A, Zanoni, M, Sangalli, M, Ghezzi, M, Fabbri, F, Sozzi, F, Dell'Acqua, V, Rigatti, P, SORANNA, DAVIDE, ZAMBON, ANTONELLA, and Rigatti, P.

Abstract

Objective: The aim of this study is to describe (urodynamically) the effect of the use of a 6-branch autologous suburethral sling, made with absorbable sutures and vas deferens, to support the bladder neck and urethra during robot-assisted laparoscopic prostatectomy (RALP) to improve early urinary continence (EUC) recovery. Materials and Methods: Retrograde leak point pressure (RLPP) was intraoperatively evaluated, by means of retrograde perfusion sphincterometry (RPS), in 77 patients (mean age-standard deviation [SD]: 65.64 +/- 7.23 years, mean body mass index +/- SD: 26.69 +/- 3.89) scheduled to undergo RALP at our institution. RLPP was evaluated before (RLPPb) and after pneumoperitoneum induction (RLPPp). RLPP was then evaluated after urethrovesical anastomosis (RLPPa) and after proper sling tensioning (RLPPs), with the aim to obtain the same pressure as after pneumoperitoneum induction. EUC recovery, defined as the use of no pad, was assessed 10 days, 30 days, and 6 months after catheter removal. Results: RPS and proper autologous 6-branch sling positioning were feasible in all patients, without perioperative complications and negligible impact on overall operative time. Pneumoperitoneum induction increased, similarly, RLPP in all patients. An important decrease of sphincteric capability was evident after prostate removal and the following urethrovesical anastomosis, while proper sling tensioning allowed for restoration of sphincteric apparatus capability to its presurgical status (mean RLPPs 40.84 cmH2O vs RLPPp 40.39 cmH2O, p = 0.942). EUC recovery within 10 days after catheter removal was achieved in 59 (77%) patients and progressively improved over time. Conclusions: RPS, intraoperatively performed during RALP, allows for precise evaluation of the impact of the surgical procedure on sphincteric apparatus competence. Moreover, the use of the 6-branch suburethral sling, in association with RPS, allows for restoration of the proper supporting system to the uret

Published
2017

24. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination

Author

Lazzeri M, Abrate A, Lughezzani G, Gadda GM, Freschi M, Mistretta F, Lista G, Fossati N, Larcher A, Kinzikeeva E, Buffi N, Dell'Acqua V, Bini V, MONTORSI , FRANCESCO, Guazzoni G., Lazzeri, M, Abrate, A, Lughezzani, G, Gadda, Gm, Freschi, M, Mistretta, F, Lista, G, Fossati, N, Larcher, A, Kinzikeeva, E, Buffi, N, Dell'Acqua, V, Bini, V, Montorsi, Francesco, and Guazzoni, G.

Published
2014

26. PO-0660: Partial breast re-irradiation with IMRT in patients with local failure after conservative treatment

Author

Dicuonzo, S., primary, Spoto, R., additional, Leonardi, M.C., additional, Surgo, A., additional, Viola, A., additional, Augugliaro, M., additional, Pansini, F., additional, Cattani, F., additional, Galimberti, V., additional, Morra, A., additional, Dell’Acqua, V., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2017
Full Text
View/download PDF

27. PO-0840: Hypofractionated intensity modulated radiotherapy in patients with immediate breast reconstruction

Author

Rojas, D.P., primary, Ricotti, R., additional, Leonardi, M.C., additional, Viola, A., additional, Dicuonzo, S., additional, Ciardo, D., additional, Cambria, R., additional, Luraschi, R., additional, Cattani, F., additional, Fodor, C., additional, Morra, A., additional, Dell'Acqua, V., additional, Galimberti, V., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2017
Full Text
View/download PDF

28. EP-1191: Postmastectomy locoregional irradiation to temporary tissue-expander or permanent breast implant

Author

Gerardi, M.A., primary, Rojas, D.P., additional, Ricotti, R., additional, Leonardi, M.C., additional, Riva, G., additional, Ciardo, D., additional, Francia, C.M., additional, Cambria, R., additional, Luraschi, R., additional, Cattani, F., additional, Fodor, C., additional, De Lorenzi, F., additional, Rietjens, M., additional, Veronesi, P., additional, Morra, A., additional, Dell’Acqua, V., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2017
Full Text
View/download PDF

31. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions.

Author

Dell'Acqua, V., Surgo, A., Kraja, F., Kobiela, J., Zerella, Maria Alessia, Spychalski, P., Gandini, S., Francia, C. M., Ciardo, D., Fodor, C., Ferrari, A. M., Piperno, G., Cattani, F., Vigorito, S., Pansini, F., Petz, W., Orecchia, R., Leonardi, M. C., and Jereczek-Fossa, B. A.

Abstract

To evaluate the local control (LC), progression free survival (PFS), out-field PFS, overall survival (OS), toxicity and failure predictors of SRT in a series of various sites oligometastatic CRC patients. Patients with oligometastatic CRC disease were analyzed retrospectively. The SRT prescribed dose was dependent on the lesion volume and its location. 102 consecutive oligometastatic CRC patients (150 lesions) were included. They underwent SRT between 2012 and 2015. Median prescription dose was 45 Gy (median dose/fraction was 15 Gy/3 fractions biological equivalent dose (BED10) 112.5 Gy). Median follow-up was 11.4 months. No patients experienced G3 and G4 toxicity. No progression was found in 82% (radiological response at 3 months) and 85% (best radiological response) out of 150 evaluable lesions. At 1 and 2 years: LC was 70% and 55%; OS was 90% and 90%; PFS was 37% and 27%; out-field PFS was 37% and 23% respectively. Progressive disease was correlated with BED10 (better LC when BED10 was ≥ 75 Gy (p < 0.0001)). In multivariate analysis, LC was higher in lesions with a Plpnning target volume (PTV) volume < 42 cm3 and BED10 ≥ 75 Gy. Patients with Karnofsky performance status < 90 showed higher out-field progression. SRT is an effective treatment for patients with oligometastases from CRC. Its low treatment-associated morbidity and acceptable LC make of SRT an option not only in selected cases. Further studies should be focused to clarify which patient subgroup will benefit most from this treatment modality and to define the optimal dose to improve LC while maintaining low toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

33. V17 Early NVBs release in RARP: The technique

Author

Ferrari, M., primary, Fabbri, F., additional, Zanoni, M., additional, Ghezzi, M., additional, Sangalli, M., additional, Sozzi, F., additional, Lolli, C., additional, Dell'Acqua, V., additional, Rigatti, P., additional, and Cestari, A., additional

Published
2016
Full Text
View/download PDF

37. La Radioterapia dei Tumori Gastrointestinali. Indicazioni e Criteri Guida

Author

Genovesi, D, Turri, L, De Paoli, A, Mattiucci, Gc, Macchia, G, Sainato, A, Lupattelli, M, Osti, Mf, Friso, Ml, Gambacorta, Ma, Mantello, G, Valvo, F, Niespolo, R, Dionisi, F, Guarneri, A, Agolli, L, Arcangeli, G, Argurio, A, Bacigalupo, A, Boz, G, Capirci, C, Caravatta, L, Ciabattoni, A, Coppola, M, Corti, L, Dell'Acqua, V, Galardi, A, Giannini, M, Innocente, R, Leonardi, Mc, Musio, D, Pani, G, Rosetto, Me, Scandolaro, L, Sciacero, P, Aristei, C, Cionini, L, Corvò, R, Morganti, Ag, Pergolizzi, Stefano, Ricardi, U, and Valentini, V.

Published
2012

45. 722 poster PERMANENT BRACHYTHERAPY AS SALVAGE THERAPY FOR LOCALLY RECURRENT PROSTATE CANCER AFTER EXTERNAL BEAM IRRADIATION.

Author

Vavassori, A., primary, Cattani, F., additional, Fodor, C., additional, Gherardi, F., additional, Comi, S., additional, Rondi, E., additional, Spoto, R., additional, Lazzari, R., additional, Jereczek-Fossa, B.A., additional, Zerini, D., additional, Dell'Acqua, V., additional, Cecconi, A., additional, de Cobelli, O., additional, Rocco, B., additional, Musi, G., additional, and Orecchia, R., additional

Published
2011
Full Text
View/download PDF

50. Ischemia acuta degli arti: considerazioni cliniche su 215 casi

Author

Comitato Scientifico, Meciani, L, Miani, S, Mingazzini, P, Dell'Acqua, V, Dell'Acqua, V., MINGAZZINI, PAOLO, Comitato Scientifico, Meciani, L, Miani, S, Mingazzini, P, Dell'Acqua, V, Dell'Acqua, V., and MINGAZZINI, PAOLO

Published
1976

Catalog

Books, media, physical & digital resources
See catalog results